Immune System Disorder — Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects
Citation(s)
A Phase 1 Randomized,Double-Blind and Parallel Controlled Single-dose Clinical Trial of Pharmacokinetics, Safety, Tolerability and Immunogenicity of HLX03 Compared With Humira® From China Source in Chinese Healthy Male Subjects